 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Public |
|---|---|
| |
| Industry | Biotechnology |
| Founded | 1916 (Federal government department), 1994 (privatised) |
| Headquarters | Parkville, Melbourne, Victoria, Australia (Global),[1] |
Key people | Paul McKenzie (CEO) |
| Products | blood plasma, vaccines, antivenom, other laboratory and medical products |
| Revenue | US$14.8 billion (2024)[2] |
 US$2.91 billion (2024)[2] | |
Number of employees | 32,000 (2024)[2] |
| Divisions | |
| Website | www |
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.[3] The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
- ^ "Annual Report 2019" (PDF). CSL Limited. 2019.
- ^ a b c "CSL Annual Report 2021/22". CSL Limited. April 2022. Retrieved 29 March 2023.
- ^ "CSL LTD (CSL:ASX): Stock Quote & Company Profile". Bloomberg Businessweek. Archived from the original on 18 January 2013. Retrieved 13 August 2012.